Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in  KRAS -mutated colorectal cancer patients

Surajit Pathak; Sushmitha S; Antara Banerjee; Francesco Marotta; Madhumala Gopinath; Ramachandran Murugesan; Hong Zhang; Bhavani B; Agniswar Girigoswami; Jose Sollano; Xiao-Feng Sun

doi:10.18632/oncotarget.22471

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients

Surajit Pathak, Sushmitha S, Antara Banerjee, Francesco Marotta, Madhumala Gopinath, Ramachandran Murugesan, Hong Zhang, Bhavani B, Agniswar Girigoswami, Jose Sollano and Xiao-Feng Sun _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:7739-7748. https://doi.org/10.18632/oncotarget.22471

Metrics: PDF 1935 views | HTML 3248 views | ?

Abstract

Surajit Pathak1, Sushmitha S1, Antara Banerjee1, Francesco Marotta2, Madhumala Gopinath1, Ramachandran Murugesan1, Hong Zhang3, Bhavani B1, Agnishwar Girigoswami1, Jose Sollano4 and Xiao-Feng Sun5

1Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India

2ReGenera Research Group for Aging-Intervention, Milano, Italy and San Babila Clinic, Healthy Aging Unit by Genomics and Biotechnology, Milano, Italy

3School of Medicine, Orebro University, Örebro, Sweden

4Gastroenterology Department, University of Santo Tomas, Manila, The Philippines

5Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

Correspondence to:

Xiao-Feng Sun, email: [email protected]

Surajit Pathak, email: [email protected]

Keywords: colorectal cancer; KRAS; bevacizumab; panitumumab; cetuximab

Received: October 15, 2016 Accepted: October 11, 2017 Published: November 16, 2017

ABSTRACT

Colorectal cancer, fourth leading form of cancer worldwide and is increasing in alarming rate in the developing countries. Treating colorectal cancer has become a big challenge worldwide and several antibody therapies such as bevacizumab, panitumumab and cetuximab are being used with limited success. Moreover, mutation in KRAS gene which is linked with the colorectal cancer initiation and progression further interferes with the antibody therapies. Considering median progression free survival and overall survival in account, this review focuses to identify the most efficient antibody therapy in combination with chemotherapy (FOLFOX-4) in KRAS mutated colorectal cancer patients. The bevacizumab plus FOLFOX-4 therapy shows about 9.3 months and 8.7 months of progression free survival for KRAS wild and mutant type, respectively. The overall survival is about 34.8 months for wild type whereas for the mutant it is inconclusive for the same therapy. In comparison, panitumumab results in better progression-free survival which is about (9.6 months) and overall survival is about (23.9 months) for the wild type KRAS and the overall survival is about 15.5 months for the mutant KRAS. Cetuximab plus FOLFOX-4 therapy shows about 7.7 months and 5.5 months of progression-free survival for wild type KRAS and mutant type, respectively. Thus, panitumumab shows significant improvement in overall survival rate for wild type KRAS, validating as a cost effective therapeutic for colorectal cancer therapy. This review depicts that panitumumab along with FOLFOX-4 has a higher response in colorectal cancer patients than the either of the two monoclonal antibodies plus FOLFOX-4.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22471

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients

Abstract